Wells Fargo analyst David Maris says Allergan's focus thus far at its aesthetics day has been on future market growth and new product rollouts. The stock is not moving much on today's news as investors want to understand that the company's plans can be accomplished within the same margin structure and not at the expense of earnings growth, Maris tells investors in an intraday research note. He believes this may be clarified later in the day and points out that some of the pipeline products will not be rolled out for some time. "So we are early in the all-day meeting, but so far, so good," Maris writes, while maintaining his Outperform rating on Allergan.